Abstracts must be submitted by Tuesday, February 1, 2022. No exceptions will be made.
Click here to access the disclosure site.
|November 1, 2021||Abstract Submission Site Opens|
|February 1, 2022||Abstract Submission Deadline*|
|May 4, 2022**||Abstract Acceptance Notifications|
|June 10, 2022||Deadline to Accept Presentation in Program and Register for Annual Meeting|
*Abstracts with authors missing completed Conflict of Interest Disclosures will NOT be reviewed.
**Date tentative and subject to change.
Abstracts submitted to the 57th Annual Meeting must fit into one of the following categories to be considered for presentation:
- Adolescent Idiopathic Scoliosis
- Adult Spinal Deformity
- Basic Science/Biomechanics/Genetics
- Case Discussion*
- Cervical Deformity
- Early Onset Scoliosis
- Miscellaneous (Spondy, Trauma, Tumor, etc.)
- Neuromuscular/Syndromic Deformity
- Non-Op Treatment Methods
*Annual Meeting Only Category
By submitting an abstract to the Annual Meeting, abstract authors are agreeing that at least one author will attend the meeting for which the abstract is accepted and will be available to present on the date and at the time assigned by the organizing committees. Authors will be notified of presentation times at the time of or shortly after notification of acceptance and are expected to make appropriate travel arrangements to ensure that at least one of the abstract’s authors will be in attendance. In addition, presenting authors are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. Abstracts for which an author is not pre-registered by the dates set forth with automatically be withdrawn from the program.
All selected authors will be required to complete a formal acceptance process by June 10 to confirm the invitation to participate in the program.
Oral Presentation Cancellation & No-Show Policy
Authors unable to present their paper in person should inform SRS as soon as possible which co-author will present in their place. If no one is able to present the paper, please inform SRS by June 10, so an alternate paper can be substituted. Please note that in the case of a "no-show" podium presentation, the presenting author associated with the "no-show" paper will be prohibited from presenting any papers at the next two Annual Meetings.
E-Poster Cancellation Policy
At least one author or co-author on all E-Posters are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. If this author cancels their registration prior to the meeting, the E-Poster may be withdrawn from the program.
Advance Presentation Submission Requirement
All presentations must clear a CME review conducted by the SRS CME Committee. Presenters may be required to submit slides for review before the meeting and may be asked to make small or significant changes if a bias issue is found. Failure to address pertinent CME review issues will result in pulling the presentation from the program and in a one year ban for abstract presentations and a three-year ban for invited presentations.
The 57th Annual Meeting will be comprised of the latest science in the field, presented as paper (podium) presentations, ePosters, symposia of invited lecturers, debates, and case discussions. Presenters will represent the best of the SRS membership, as well as non-members, from an international group of physicians and researchers. The Scientific Papers and ePosters will be selected by the Program Committee, based on a blinded review of submissions.
The SRS Annual Meeting will continue to be the scientific forum for presenting the latest clinical and basic science and translational medicine research on spinal deformity topics. A minimum two (2) year follow-up of outcome studies with strong scientific rigor will be emphasized for selection of abstracts for presentation. Studies with a focus on robust enrollment and longer-term follow-up of technologies previously presented at IMAST are encouraged to be submitted to the Annual Meeting. In addition, clinical series highlighting unique problems associated with longer-term follow-up in the management of spinal deformity patients will also be strongly considered for presentation.
- Program divided equally between adult deformity & pediatric deformity
- 3 day program plus Pre-Meeting Course, including papers, Case Discussions, Half-Day Courses, Lunchtime Symposia and ePosters
- Two-year clinical follow-up required for free paper submissions
In addition, it is the SRS policy that members can only present two abstracts, and non-members can only present one abstract at the podium.
Who Should Attend?
The 57th Annual Meeting is open to anyone involved in the treatment of spinal disorders including spine surgeons, residents and fellows, physician assistants, nurses and other allied health professionals, and researchers. The presentations selected will provide valuable information to all individuals caring for patients with spinal deformities.
Abstracts must be submitted online via https://owpm1.com/abstracts/SRSAM/.
Abstract Review Process
- All abstracts submitted will be reviewed and graded in blinded fashion by the Program Committee.
- Two-year follow-up is required for papers submitted to the Annual Meeting.
- Based upon abstract grading, those selected will be assigned to a four-minute oral presentation or three-minute E-Poster.
- The review process takes approximately 3-4 weeks. Acceptance notification will be made by email by May 2, 2022.
Disclosure and Licensing Requirement
All abstract authors will be required to submit a Financial Disclosure Statement, an FDA Disclosure Form, an Attestation and Non-Exclusive Licensing Agreement during the online submission process. ALL authors listed on an abstract will be required to submit a financial disclosure form, including disclosure of ALL financial relationships, not only those pertaining to the topic of the abstract. In the event that all authors on an abstract have not completed these required forms prior to the submission deadline of February 1, 2022 the abstract will NOT be reviewed or considered for the Annual Meeting program.
Visit this link to disclose: https://owpm1.com/abstracts/SRSAM/disclosure
The username is the email associated with your abstract and the password your first name.
Submission length is limited to 2,500 characters.
Characters in the abstract title, body and table/image caption will be counted (including spaces). Characters in the author and institution listing will not be counted. There is a strict limit of one graph, figure or table to each submitted abstract. NO EXCEPTIONS WILL BE MADE.
Previous Publication or Presentation
Abstracts which have been published in journals, meeting proceedings, or other publication, as well as those presented at meetings prior to the SRS meeting to which authors wish to submit are NOT eligible for submission. Only abstracts that have NOT been previously published or presented are eligible for submission.
The term “hardware” should not be used in written abstract submissions, oral presentations and E-Poster presentations. The terms “instrumentation,” “implants,” “constructs,” or “montage” should be used instead.
SRS strongly prefers that surgical approaches or specific instrumentation such as “Isola, TSRH, CD, XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in presentations. These terms should be replaced by a generic description of the instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque). Company names and logos must never be used in a presentation.
It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any potential conflict of interest. When there is a known potential conflict of interest, an expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.
For questions about abstracts, please contact the SRS Education team at firstname.lastname@example.org.